Elan Corporation News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

27.11.12	Elan Announces Enrollment of First Patient in Phase 2 Study of ELND005 (Scyllo-inositol) for the Treatment of Agitation/Aggression in Patients with Alzheimer’s Disease (Businesswire)
26.11.12	2iQ Research / Die wöchentliche Top 10 der grössten Insidertransaktionen (Dow Jones)
20.11.12	ROUNDUP/Wall Street hat neuen Insiderfall: 'Lukrativster Tipp aller Zeiten' (dpa-afx)
13.11.12	Elan Announces Publication of EGM Circular in Respect of Proposed Demerger (Businesswire)
24.10.12	Elan Reports Third Quarter 2012 Financial Results (Businesswire)
23.10.12	Elan Announces Expiration of Cash Tender Offer and Consent Solicitation for 8.75% Senior Notes due 2016 (Businesswire)
11.10.12	TYSABRI® (natalizumab) DATA AT ECTRIMS REAFFIRM POSITIVE EFFECTS OF TREATMENT FOR PEOPLE WITH RELAPSING FORMS OF MS (Businesswire)
10.10.12	Elan Announces Webcast of Third Quarter 2012 Financial Results (Businesswire)
08.10.12	Elan Announces Results Through Consent Payment Deadline of Cash Tender Offer and Consent Solicitation for 8.75% Senior Notes Due 2016 (Businesswire)
01.10.12	Elan Announces Redemption of Its Senior Notes Due 2016 (Businesswire)
25.09.12	Elan Announces Pricing of $600 Million 2019 Senior Notes (Businesswire)
25.09.12	Elan Finance plc -- Moody's rates Elan's sr. notes B1; under review for upgrade (Moodys)
25.09.12	Elan Announces Intent to Offer US$500 Million in Aggregate Principal Amount of Senior Notes Due 2019 (Businesswire)
24.09.12	Elan Announces Commencement of Tender Offer and Consent Solicitation (Businesswire)
20.09.12	Elan Announces the Appointment of Hans Peter Hasler as Chief Operating Officer (Businesswire)
03.09.12	Die wöchentliche Top 10 der Insidertransaktionen (Dow Jones)
29.08.12	Elan Announces Dosing of First Patient in Phase 2 Trial of ELND005 (Scyllo-inositol) in Bipolar Disorder (Businesswire)
27.08.12	Die wöchentliche Top 10 der Insidertransaktionen (Dow Jones)
13.08.12	Elan Finance plc -- Moody's reviews Elan's B1 rating for upgrade (Moodys)
13.08.12	Elan Announces Plan to Spin-Off Discovery Science And Neotope Biosciences to Shareholders (Businesswire)
07.08.12	Elan Corporation, plc -- Moody's: Discontinuation of bapineuzumab IV is credit negative for Elan (Moodys)
07.08.12	Aktien New York: Weitere Gewinne - Aufwärtstrend setzt sich fort (dpa-afx)
07.08.12	Wall Street Freundlich - Aufwärtstrend setzt sich fort (dpa-afx)
07.08.12	Aktien New York Ausblick: Freundlich - Aufwärtstrend dürfte sich fortsetzen (dpa-afx)
06.08.12	Elan Announces Johnson & Johnson Release of Discontinuation of Phase 3 Development of Bapineuzumab Intravenous (IV) In Mild to Moderate Alzheimer’s Disease (Businesswire)
25.07.12	Elan Reports Second Quarter and First Half 2012 Financial Results (Businesswire)
24.07.12	Wall Street mit Verlusten (dpa-afx)
24.07.12	Aktien New York: Minus ausgeweitet - Eurokrise, Konjunkturdaten (dpa-afx)
24.07.12	ROUNDUP/Aktien New York: Verluste - Eurokrise und Konjunkturdaten belasten (dpa-afx)
24.07.12	Aktien New York Ausblick: Leichtes Minus - Moody's warnt, gute Daten aus China (dpa-afx)
24.07.12	Elan Announces Pfizer’s Release of A Top-Line Result In First Of Four Bapineuzumab Phase 3 Trials (Businesswire)
12.07.12	Elan Announces Webcast of Second Quarter 2012 Financial Results (Businesswire)
11.07.12	Elan-UCD endowment honours Irish business leaders and boosts Ireland’s capacity in the 'Business of Biotechnology' (Businesswire)
28.05.12	Elan to Present at Jefferies 2012 Global Healthcare Conference (Businesswire)
17.05.12	New Analysis of Risk Stratification for TYSABRI® Published in New England Journal of Medicine (Businesswire)
27.04.12	Elan to Present at Deutsche Bank 37th Annual Healthcare Conference (Businesswire)
26.04.12	NEW TYSABRI DATA PRESENTED AT 64TH ANNUAL AAN MEETING HIGHLIGHT BIOGEN IDEC & ELAN COMMITMENT TO IMPROVING OUTCOMES IN MULTIPLE SCLEROSIS (Businesswire)
26.04.12	Elan Reports First Quarter 2012 Financial Results (Businesswire)
12.04.12	Elan Announces Webcast of First Quarter 2012 Financial Results (Businesswire)
13.03.12	Elan Raises $381 Million in Sale of 76% of Alkermes Holding (Businesswire)
01.03.12	Elan Chairman Provides Update on CEO Succession (Businesswire)
23.02.12	Elan Announces Filing of Annual Report on Form 20-F for Year Ended December 31, 2011 (Businesswire)
21.02.12	Elan to Present at Cowen & Co., 32nd Annual Healthcare Conference (Businesswire)
08.02.12	Elan Reports Fourth Quarter and Full-Year 2011 Financial Results (Businesswire)
01.02.12	Elan to Present at the Leerink Swann 2012 Global Healthcare Conference (Businesswire)
26.01.12	ASCEND Study to Evaluate the Effectiveness of TYSABRI® (natalizumab) as a Treatment for Secondary-Progressive Multiple Sclerosis (Businesswire)
20.01.12	FDA Updates TYSABRI® (natalizumab) Label to Include Anti-JC Virus Antibody Status as a PML Risk Factor (Businesswire)
12.12.11	University College Dublin and Elan Announce Initiative to Create Leadership in Biotechnology (Businesswire)
29.11.11	Elan Provides an Update on ELND005 (Scyllo-inositol) (Businesswire)
28.11.11	Cambridge-Elan Centre for Research Innovation and Drug Discovery Launched (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Holcim	94.20	3.65 %	K V
UBS Group	30.16	3.64 %	K V
Sika	233.30	2.73 %	K V
Geberit	517.00	2.25 %	K V
Part Grp Hldg	1’418.00	1.61 %	K V
Alcon	83.58	-0.29 %	K V
CieFinRichemont	176.90	-0.45 %	K V
Sonova Hldg	306.50	-0.81 %	K V
Novartis	97.71	-0.88 %	K V
Roche Hldg G	287.70	-1.24 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Elan Corporation PLC (spons. ADRs)

Aktien Top/Flop

Meistgelesene Nachrichten